In an interview, Lars Rebien, the Chief Executive of Novo Nordisk AS, said that they are optimistic in receiving approval for the new drug and expect distribution to commence by mid 2009. Rebien further says that liraglutide might also be marketed as a weight-control drug.SANDSTROM...
Novo Nordisk is striking a delicate balance as the drugmaker seeks meeting pent-up demand in China while taking advantage of wheat may only be a brief head start on its U.S. rival Eli Lilly & Co., Bloomberg commented. It noted Lilly’s popular obesity drug Zepbound is under regulatory r...
This is a guest preview - full data is available to DRUGANALYST subscribers. For Subscription Enquires please contact us NOVO: T&Ds 22 Oct 2024 - NOVO: News Not Views Some strange wording. They claimed the “headline” results from the SOUL cardiovascular outcomes trial of Rybelsus vs ...
said he received commitments in writing from all of the major PBMs that they would not limit coverage of Wegovy and Ozempic if Novo Nordisk reduced their list prices.The hearing comes roughly five months after Sanders opened an investigation into the Danish drugmaker’s pricing practices...
In a statement, Novo Nordisk said all doses of Wegovy and Ozempic are being shipped regularly to wholesalers. The Danish drugmaker said the FDA’s update is a result of the company’s significant investment in expanding manufacturing capacity and “ongoing communication” with the agency. ...
NVO-1.98% Novo Nordisk: The US Food and Drug Administration (FDA) approved Wegovy's scope of application and can now be used to reduce the risk of serious adverse cardiovascular events. According to SELECT cardiovascular clinical trial results, Wegovy showed significant statistical significance, reduc...
BEIJING, June 6 (TMTPost) -- Novo Nordisk has submitted application for the approval of semaglutide injection for weight loss to China's regulator, according to the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration. ...
In China the drug is used in injected-form, but Novo Nordisk is starting to introduce it in tablet form in other countries. The drug has been taking the US by storm as a weight-loss drug under the name Wegovy. As a result, sales have trebled from DKK4.5 billion (USD645.7 million) ...
Novo Nordisk on Thursday put more than $1 billion on the line to buy Canadian biotech Inversago Pharma, further beefing up its already-formidable obesity and diabetes portfolio. The acquisition agreement comes amid record sales of Novo’s weight-loss drug Wegovy (semaglutide), which during the ...
Novo Nordisk's flagship weight-loss drug Wegovy has been approved for use in China, the Danish pharmaceutical giant said. The company — Europe's largest by market capitalization — confirmed to AFP on Tuesday that China had...